{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T09:10:55Z","timestamp":1760778655680,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007033","name":"Eisai Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.breast.2020.09.004","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T02:30:40Z","timestamp":1600223440000},"page":"121-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1504-3815","authenticated-orcid":false,"given":"Min Ho","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Chul","family":"Noh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Wan","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil Soo","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-In","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Soo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Jin","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geumhee","family":"Gwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Bum","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9713-2605","authenticated-orcid":false,"given":"Hyun-Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3245-9038","authenticated-orcid":false,"given":"Min Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0397-0005","authenticated-orcid":false,"given":"Joon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2020.09.004_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2020.09.004_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4068\/cmj.2018.54.2.90","article-title":"Updates on cancer epidemiology in Korea","volume":"54","author":"Kweon","year":"2018","journal-title":"Chonnam Med J"},{"key":"10.1016\/j.breast.2020.09.004_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/bcr932","article-title":"The changing global patterns of female breast cancer incidence and mortality","volume":"6","author":"Bray","year":"2004","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2020.09.004_bib4","first-page":"519M","article-title":"Metastatic breast cancer","volume":"88","author":"Peart","year":"2017","journal-title":"Radiol Technol"},{"key":"10.1016\/j.breast.2020.09.004_bib5","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","article-title":"The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth","volume":"4","author":"Jordan","year":"2005","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.breast.2020.09.004_bib6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/bi901810u","article-title":"Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability","volume":"49","author":"Smith","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.breast.2020.09.004_bib7","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.cub.2016.04.053","article-title":"Termination of protofilament elongation by eribulin induces lattice defects that promote microtubule catastrophes","volume":"26","author":"Doodhi","year":"2016","journal-title":"Curr Biol"},{"key":"10.1016\/j.breast.2020.09.004_bib8","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","article-title":"Introduction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389","volume":"64","author":"Kuznetsov","year":"2004","journal-title":"Canc Res"},{"key":"10.1016\/j.breast.2020.09.004_bib9","first-page":"1013","article-title":"In\u00a0vitro and in\u00a0vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B","volume":"61","author":"Towle","year":"2001","journal-title":"Canc Res"},{"key":"10.1016\/j.breast.2020.09.004_bib10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/0008-5472.CAN-10-1874","article-title":"Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in\u00a0vivo efficacy under intermittent dosing conditions","volume":"71","author":"Towle","year":"2011","journal-title":"Canc Res"},{"key":"10.1016\/j.breast.2020.09.004_bib11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","article-title":"Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies","volume":"148","author":"Twelves","year":"2014","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2020.09.004_bib12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1186\/s12885-017-3846-8","article-title":"Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study","volume":"17","author":"Iizumi","year":"2017","journal-title":"BMC Canc"},{"key":"10.1016\/j.breast.2020.09.004_bib13","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician\u2019s Choice versus E7389) investigators. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2020.09.004_bib14","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.09.004_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/IJWH.S74462","article-title":"Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy","volume":"7","author":"Doherty","year":"2015","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.breast.2020.09.004_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000176","article-title":"Eribulin for metastatic breast cancer (MBC) treatment: a retrospective multicenter study based in Campania, south Italy (Eri-001 trial)","volume":"2","author":"Orditura","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2020.09.004_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","article-title":"Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial","volume":"112","author":"Yuan","year":"2019","journal-title":"Eur J Canc"},{"key":"10.1016\/j.breast.2020.09.004_bib18","first-page":"77","article-title":"Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer","volume":"10","author":"Twelves","year":"2016","journal-title":"Breast Cancer (Auckl)"},{"key":"10.1016\/j.breast.2020.09.004_bib19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4048\/jbc.2016.19.1.8","article-title":"Asian Working Group for Eribulin Clinical Guide. Patient management with eribulin in metastatic breast cancer: a clinical practice guide","volume":"19","author":"Ro","year":"2016","journal-title":"J\u00a0Breast Cancer"},{"key":"10.1016\/j.breast.2020.09.004_bib20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/1759-7714.12482","article-title":"Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice","volume":"8","author":"Tanaka","year":"2017","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.breast.2020.09.004_bib21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10637-017-0486-4","article-title":"Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study","volume":"35","author":"Watanabe","year":"2017","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.breast.2020.09.004_bib22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4143\/crt.2016.191","article-title":"Feasibility and efficacy of eribulin mesylate in Korean patients with metastatic breast cancer: Korean multi-center Phase IV clinical study results","volume":"49","author":"Park","year":"2017","journal-title":"Cancer Res Treat"},{"year":"2009","series-title":"Cancer therapy evaluation program","key":"10.1016\/j.breast.2020.09.004_bib23"},{"key":"10.1016\/j.breast.2020.09.004_bib24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000489063","article-title":"Eribulin in heavily pretreated metastatic breast cancer patients in the real world: a retrospective study","volume":"94","author":"Pedersini","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.breast.2020.09.004_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40064-016-1700-0","article-title":"Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life","volume":"5","author":"Garrone","year":"2016","journal-title":"SpringerPlus"},{"key":"10.1016\/j.breast.2020.09.004_bib26","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1002\/ijc.32402","article-title":"Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program","volume":"145","author":"Jacot","year":"2019","journal-title":"Int J Canc"},{"key":"10.1016\/j.breast.2020.09.004_bib27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10549-018-4778-y","article-title":"Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan","volume":"170","author":"Rau","year":"2018","journal-title":"Breast Canc Res Treat"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977620301818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977620301818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:42:24Z","timestamp":1760776944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977620301818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":27,"alternative-id":["S0960977620301818"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2020.09.004","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2020.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}